Add to Watchlist
View Current for BLUE
View SuperFeed for BLUE
View Charts for BLUE
Add or remove $BLUE from your watchlists:
Hang tight! We're updating your watchlist data.
This might take a minute...
Bluebird bio Inc
Health Care
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candida… more
Thread Explorer
Explore popular threads around $BLUE
There are no threads for this stock
Go to Thread Explorer
Chart Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Latest News
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Company Profile
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Market Cap Type: Small